The U.S. Food and Drug Administration on Thursday approved Gilead Sciences’ antiviral drug remdesivir as a treatment for COVID-19 patients requiring hospitalization.
As per John Hopkins University, this drug is the first fully approved treatment in the U.S. for the novel coronavirus, which has killed more than 1.1 million people worldwide.
In May, Remdesivir, sold under the brand name Veklury, was granted an emergency approval by the FDA.
The U.S. National Institutes of Health did a study and found that this drug has reduced recovery time from 15-10 days on average to five days.
According to the California-based Gilead Sciences, Veklury is approved for people older than 12 years old, weighing at least 88 pounds, and who need hospitalization for their treatment.
Gilead CEO Daniel O’Day stated, “Since the beginning of the COVID-19 pandemic, Gilead has worked relentlessly to help find solutions to this global health crisis.”
“It is incredible to be in the position today, less than one year since the earliest case reports of the disease now known as COVID-19, of having an FDA-approved treatment in the U.S. that is available for all appropriate patients in need,” he added.
This drug is approved for usage in the United Kingdom and Europe and is among the treatments U.S. President Donald Trump received when he was tested positive for the virus.